Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
NOT YET RECRUITING
NCT06633042
PHASE1

The Safety and Efficacy of Universal CAR-T Cells Targeting BCMA in the Treatment of Refractory NMOSD

Sponsor: Bioray Laboratories

View on ClinicalTrials.gov

Summary

This is an open label, Multi-center,dose-escalation study in up to 18 participants with refractory NMOSD. This study aims to evaluate the safety and efficacy of universal CAR-T Cells targeting BCMA in the Treatment of refractory NMOSD.

Official title: The Safety and Efficacy of Universal CAR-T Cells Targeting BCMA in the Treatment of Refractory AQP4 Antibody Positive Neuromyelitis Optica Spectrum Disease

Key Details

Gender

All

Age Range

18 Years - 65 Years

Study Type

INTERVENTIONAL

Enrollment

18

Start Date

2024-11-25

Completion Date

2025-12-12

Last Updated

2024-11-12

Healthy Volunteers

No

Interventions

DRUG

Universal BCMA-CD19 CART

1.0-4.0×10\^6 CAR-T cells/kg